| abstract |
The use of a compound effective to inhibit the binding of a beta amyloid peptide with the nicotinic alpha-7 acetylcholine receptors in the manufacture of a medicament for treating a neurodegenerative disorder, in which the compound has formula I in which R1 is hydrogen or C1-C4 alkyl; R2 is selected from hydrogen, C1-C6 alkyl or aryl or C7-C10 aralkyl; R3 is selected from hydrogen, C1-C6 alkyl, C3-C10 alkenyl, C3-C8 cycloalkyl C1-C6 alkyl, heteroaryl C1-C4 alkyl, substituted or unsubstituted aryl or substituted or unsubstituted C7-C10 aralkyl, where the substituent of the aryl or aralkyl are one or more substituents independently selected from the group consisting of halogen, hydroxy, C1-C6 alkyl and substituted or unsubstituted C1-C6 alkoxy in which the alkoxy substituents are one or more substituents independently selected from amino, alkylamino C1-C6, C1-C6 dialkylamino, pyrrolidinyl, piperidinyl, azepinyl or morpholino; or R2 and R3, together with the nitrogen to which they are attached, form a five or six membered heterocyclic ring selected from pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl; R4 is C1-C6 alkyl, aryl or C7-C10 aralkyl; and Each of R5 and R6 is independently selected from hydrogen, C1-C6 alkyl, C3-C10 alkenyl, C1-C8 alkylcarbonyl or diphenylphosphinyl; and pharmaceutically acceptable salts and prodrugs thereof. |